| Absorption | Distribution | Metabolism | Excretion | Special Population (N/A) | Other Details |
Absorption
Plasma Concentration
(5 healthy adults under fasting conditions, single administration of 5 mg of mosapride citrate)
| Tmax (h) | Cmax (ng/mL) | T1/2 (h) | AUC0-∞ (ng∙h/mL) |
| 0.8±0.1 | 30.7±2.7 | 2.0±0.2 | 67±8 |
Distribution
Plasma Protein Binding Rate
99.0% [in vitro, human serum, at a concentration of 1 μg/mL, methods of ultrafiltration or equilibrium dialysis]
Metabolism
Metabolic Enzyme: Cytochrome P-450 sub-family: mainly CYP3A4.
Main metabolite: Des-4-fluorobenzyl-mosapride
Metabolic pathway: Mosapride citrate is metabolized mainly in the liver, where the 4-fluorobenzyl group is removed, followed by oxidation of the morpholine ring at position 5, and hydroxylation of the benzene ring at position 3.
Excretion
Excretion route: In urine and feces
Excretion rate: In urine collected for 48 hours after administration, 0.1% was excreted as unchanged compound and 7.0% was excreted as the main metabolite (des-4-fluorobenzyl mosapride). (Healthy adults, single administration of 5 mg of mosapride citrate under fasting conditions)
Special Population
N/A
Other details
Drug interactions
When erythromycin at 1,200 mg/day was concomitantly administered with this drug at 15 mg/day, in comparison with a single administration of mosapride, maximum blood concentration of mosapride increased from 42.1 ng/mL to 65. 7 ng/mL, the half-life was prolonged from 1 .6 hours to 2.4 hours and AUC0-4 increased from 62 ng•hr/mL to 114 ng•hr/mL. (Healthy adult).
